<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22024" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Galactorrhea</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gosi</surname>
            <given-names>Shiva Kumar Y.</given-names>
          </name>
          <aff>Banner Thunderbird Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Garla</surname>
            <given-names>Vishnu V.</given-names>
          </name>
          <aff>University of Mississippi Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shiva Kumar Gosi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vishnu Garla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22024.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Galactorrhea is milk production from the breast unrelated to pregnancy or lactation. Milk production one year after cessation of breastfeeding is non-lactational and is considered galactorrhea. Various hormones including prolactin, estrogens, thyrotropin-releasing hormone (TRH) can affect the production of milk. This activity reviews the evaluation of galactorrhea and the role of the interprofessional team in treating this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the signs and symptoms of galactorrhea.</p></list-item><list-item><p>Identify the hormones that affect milk production.</p></list-item><list-item><p>Summarize the treatment for gallactorrhea.</p></list-item><list-item><p>Review the evaluation of galactorrhea and the role of the interprofessional team in treating this condition.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22024&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22024">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22024.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Galactorrhea is milk production from the breast unrelated to pregnancy or lactation. Milk production one year after cessation of breastfeeding is non-lactational and is considered galactorrhea. Various hormones including prolactin, estrogens, thyrotropin-releasing hormone (TRH) can affect the production of milk.<xref ref-type="bibr" rid="article-22024.r1">[1]</xref></p>
      </sec>
      <sec id="article-22024.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The various causes of galactorrhea broadly divide into hypothalamic-pituitary causes and non-hypothalamic-pituitary causes.</p>
        <p>Hypothalamic-pituitary causes:</p>
        <list list-type="order">
          <list-item>
            <p>&#x000a0;Prolactinomas: Prolactinomas are prolactin-secreting tumors and are the commonest hormone-secreting tumors of the pituitary glands. Prolactinomas which are less than 1 cm in size&#x000a0;are known as microprolactinomas, whereas those&#x000a0;greater than 1 cm in size are known as macroprolactinomas. Prolactin levels correlate well with the size of the tumor with microprolactinomas having prolactin levels of &#x0003e;200 ng/ml and macroprolactinomas having higher prolactin levels of &#x0003e;1000 ng/ml.</p>
          </list-item>
          <list-item>
            <p>Non-prolactin-secreting pituitary tumor and infiltrative disorders of the pituitary stalk/hypothalamus: These tumors can cause hyperprolactinemia by disrupting the flow of dopamine from the hypothalamus to the anterior pituitary by compressing the pituitary stalk. This disruption results in decreased inhibition of prolactin and results in mild hyperprolactinemia, usually less than 200 ng/ml.<xref ref-type="bibr" rid="article-22024.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>Non-hypothalamic-pituitary causes:</p>
        <list list-type="order">
          <list-item>
            <p>Hypothyroidism: Elevated levels of TRH&#x000a0;in hypothyroidism can stimulate the lactotrophs resulting in hyperprolactinemia and galactorrhea.</p>
          </list-item>
          <list-item>
            <p>Medications: Several medications can cause hyperprolactinemia and galactorrhea. In most instances, the level of prolactin is less than 200 ng/ml; however, atypical antipsychotics like risperidone carry associations with prolactin levels of &#x0003e;200 ng/ml, which can&#x000a0;be confused&#x000a0;for a microprolactinoma.&#x000a0;Atypical antipsychotics act on the D2 receptors in the hypothalamic tuberoinfundibular areas to cause hyperprolactinemia. Risperidone is a combined dopamine serotonin antagonist which can significantly raise the prolactin levels. Clozapine, olanzapine, and aripiprazole have both agonist and antagonist properties on the D2 receptor and only transiently raise the prolactin levels. Metoclopramide and domperidone, which are used in the treatment of vomiting, are D2 receptor blockers and cause hyperprolactinemia. Tricyclic antidepressants (especially clomipramine) and monoamine-oxidase inhibitors have been associated with mild hyperprolactinemia. The mechanisms by which these medications cause hyperprolactinemia is unknown.&#x000a0; Opioids by acting through the &#x000b5; receptors decrease the release of hypothalamic dopamine and can elevate prolactin levels. Verapamil has also been associated with hyperprolactinemia by decreasing the production of hypothalamic dopamine.<xref ref-type="bibr" rid="article-22024.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Renal failure: Hyperprolactinemia in renal failure is&#x000a0;due to the failure of the kidneys to clear prolactin. Prolactin levels of &#x0003e;1000 mcg/liter have been reported with renal failure. Post-kidney transplant the hyperprolactinemia resolves rapidly within a few days.</p>
          </list-item>
          <list-item>
            <p>Chest wall lesions: Various chest wall lesions including burns, surgeries, herpes zoster have associations with hyperprolactinemia. The hypothesis is that the pain signals transmit to the hypothalamus via the spinal cord which results in decreased dopamine release and causes hyperprolactinemia.</p>
          </list-item>
          <list-item>
            <p>Idiopathic hyperprolactinemia: Occasionally hyperprolactinemia with no known cause has been reported. These could be secondary to small undiagnosed microprolactinomas. The hyperprolactinemia self resolves in 1/3rd patients and remains stable in half of the patients.<xref ref-type="bibr" rid="article-22024.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22024.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hyperprolactinemia is more common in women. The prevalence of hyperprolactinemia ranges from 0.4% in an unselected normal adult population to as high as 9 to 17% in women with reproductive disorders. Its prevalence was found to be as high as 17% among women with polycystic ovary syndrome.&#x000a0;<xref ref-type="bibr" rid="article-22024.r4">[4]</xref></p>
      </sec>
      <sec id="article-22024.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Prolactin is responsible for the synthesis and secretion of milk. Prolactin is secreted by the lactotroph cells in the anterior pituitary. Dopamine secreted from the hypothalamus inhibits the secretion of prolactin. TRH and vasoactive intestinal polypeptide can stimulate prolactin secretion. Also, nipple stimulation, renal failure, chest wall lesions, and medications can cause hyperprolactinemia.<xref ref-type="bibr" rid="article-22024.r1">[1]</xref><xref ref-type="bibr" rid="article-22024.r5">[5]</xref></p>
        <p>Estrogens cause hyperprolactinemia by inhibiting hypothalamic dopamine as well as stimulating lactotrophs directly. In pregnancy, the high levels of estrogen cause lactotroph hyperplasia and can even result in the growth of a preexisting prolactinoma. Excess secretion of estrogen from ovaries in ovarian hyperstimulation syndrome has also been associated with hyperprolactinemia.<xref ref-type="bibr" rid="article-22024.r6">[6]</xref><xref ref-type="bibr" rid="article-22024.r7">[7]</xref></p>
      </sec>
      <sec id="article-22024.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Careful assessment of hyperprolactinemic related symptoms menstrual irregularities, decreased libido, galactorrhea, erectile dysfunction, infertility, and gynecomastia should be performed. Detailed medication history is important when considering medication induced hyperprolactinemia. If a pituitary lesion is suspected then evaluation for headaches, and visual deficits are in order.</p>
        <p>For assessing galactorrhea on physical exam, the patient needs to be sitting and leaning forward. The areola needs to be squeezed in the direction of the nipple. The galactorrhea is usually bilateral and can be white or green. Bloody discharge could be due to breast tumors and will need further workup in that direction.&#x000a0; A Sudan IV stain for fat droplets can confirm whether the discharge is milk or not.<xref ref-type="bibr" rid="article-22024.r2">[2]</xref></p>
      </sec>
      <sec id="article-22024.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Prolactin levels need to be taken at least once in the evaluation of hyperprolactinemia. Prolactin levels are measured using a sandwich ELISA assay where a prolactin molecule needs to bind to a capture as well as a detection antibody to be measured. Rarely the &#x0201c;hook effect&#x0201d; may be seen in large prolactinomas with an extremely high prolactin level. Due to the extremely&#x000a0;high prolactin levels, the number of prolactin molecules binding to both the capture and detection antibody is actually&#x000a0;low. Dilution of the sample to a 1:100 concentration and remeasuring shows a paradoxical increase in the prolactin level. The &#x0201c;hook effect&#x0201d; needs to be considered in large pituitary adenomas which present with galactorrhea, hypogonadism but only mildly elevated levels of prolactin.<xref ref-type="bibr" rid="article-22024.r8">[8]</xref><xref ref-type="bibr" rid="article-22024.r9">[9]</xref></p>
        <p>Hormonal assessment of other pituitary hormones should be taken as indicated by the clinical history and exam. Magnetic resonance imaging (MRI) of the pituitary gland may reveal lesions of the pituitary gland responsible for hyperprolactinemia. Visual field assessment needs to be performed when the tumor is in contact with the optic chiasma on MRI.<xref ref-type="bibr" rid="article-22024.r2">[2]</xref></p>
      </sec>
      <sec id="article-22024.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>After ruling out breast pathologies, therapy direction is towards the cause of hyperprolactinemia. Hyperprolactinemia is treated if there is a pituitary lesion or hypogonadism with problematic galactorrhea; if not troublesome, it can be monitored without therapy.</p>
        <p>The mainstay of hyperprolactinemia is treatment with bromocriptine or cabergoline. These are dopamine agonists which act on the D2 receptors present on the lactotrophs and inhibit prolactin production. The doses for bromocriptine and cabergoline are 2.5-15 mg once daily and cabergoline 0.25-1 mg twice weekly, respectively. They are effective at normalizing prolactin levels as well as shrinking the size of the tumor. Side effects include nausea, vomiting, orthostatic hypotension, drowsiness, and headaches. Cardiac valvulopathy has been reported with high doses of cabergoline, and it is recommended to get an annual echocardiogram in patients on more than 3.5 mg/week.</p>
        <p>In cases of medication-induced hyperprolactinemia, the offending medication should be stopped or changed to a different class. Use of dopamine agonists in these instances has associations with a slight risk of exacerbating the psychiatric disorder.</p>
        <p>Normoprolactinemic galactorrhea occurs when the galactorrhea accompanies normal prolactin levels. If symptomatic with troublesome galactorrhea or menstrual cycle irregularities it can be treated with dopamine agonists to obtain symptomatic relief. The treatment is tapered off once the galactorrhea has resolved.<xref ref-type="bibr" rid="article-22024.r2">[2]</xref><xref ref-type="bibr" rid="article-22024.r1">[1]</xref></p>
      </sec>
      <sec id="article-22024.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acromegaly</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Breast stimulation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bronchogenic carcinoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Burns</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Breast surgery</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Craniopharyngioma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cushing's disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chest wall irritation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Idiopathic</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lymphoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Molar pregnancy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Meds and herbs</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pituitary adenomas</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal failure</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sarcoid</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>TB</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22024.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Galactorrhea is nonlactational production of milk. Prolactin, estrogens, and TRH all play a role in the production of milk from the breast. The condition is often managed by an interprofessional team that consists of a radiologist, endocrinologist, neurosurgeon, neurologist, and an internist. The galactorrhea associated with hyperprolactinemia is often&#x000a0;associated with symptoms of hypogonadism (decreased libido, erectile dysfunction, and menstrual irregularities) and thus a thorough medical history and physical exam are needed.&#x000a0;Serosanguinous discharge from the breast should prompt further evaluation for breast pathologies. Inquiring of the patient about their current medications is vital. In most cases, treatment with dopamine agonists (cabergoline or bromocriptine) normalizes prolactin levels and results in shrinkage of the tumor. (Level V)</p>
      </sec>
      <sec id="article-22024.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22024&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22024">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/womens-health/galactorrhea/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22024">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22024/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22024">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22024.s12">
        <fig id="article-22024.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Prolactinoma MRI Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="prolactinoma1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22024.s13">
        <title>References</title>
        <ref id="article-22024.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Molitch</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and management of galactorrhea.</article-title>
            <source>Am Fam Physician</source>
            <year>2012</year>
            <month>Jun</month>
            <day>01</day>
            <volume>85</volume>
            <issue>11</issue>
            <fpage>1073</fpage>
            <page-range>1073-80</page-range>
            <pub-id pub-id-type="pmid">22962879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22024.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casanueva</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kleinberg</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Montori</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Schlechte</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wass</surname>
                <given-names>JA</given-names>
              </name>
              <collab>Endocrine Society</collab>
            </person-group>
            <article-title>Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>273</fpage>
            <page-range>273-88</page-range>
            <pub-id pub-id-type="pmid">21296991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22024.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molitch</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Drugs and prolactin.</article-title>
            <source>Pituitary</source>
            <year>2008</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-18</page-range>
            <pub-id pub-id-type="pmid">18404390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22024.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vroonen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Beckers</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and Management Challenges in Prolactinomas.</article-title>
            <source>Neuroendocrinology</source>
            <year>2019</year>
            <volume>109</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-27</page-range>
            <pub-id pub-id-type="pmid">30731464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22024.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freeman</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kanyicska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lerant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prolactin: structure, function, and regulation of secretion.</article-title>
            <source>Physiol Rev</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>1523</fpage>
            <page-range>1523-631</page-range>
            <pub-id pub-id-type="pmid">11015620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22024.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christin-Ma&#x000ee;tre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delemer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Touraine</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>68</volume>
            <issue>2-3</issue>
            <fpage>106</fpage>
            <page-range>106-12</page-range>
            <pub-id pub-id-type="pmid">17540335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22024.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morel</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Car&#x000f3;n</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>C&#x000f3;nsole</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Soaje</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Jahn</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Goya</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Estrogen inhibits tuberoinfundibular dopaminergic neurons but does not cause irreversible damage.</article-title>
            <source>Brain Res Bull</source>
            <year>2009</year>
            <month>Dec</month>
            <day>16</day>
            <volume>80</volume>
            <issue>6</issue>
            <fpage>347</fpage>
            <page-range>347-52</page-range>
            <pub-id pub-id-type="pmid">19744546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22024.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barkan</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chandler</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report.</article-title>
            <source>Neurosurgery</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>913</fpage>
            <page-range>913-5; discussion 915-6</page-range>
            <pub-id pub-id-type="pmid">9574657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22024.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chahal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schlechte</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hyperprolactinemia.</article-title>
            <source>Pituitary</source>
            <year>2008</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-6</page-range>
            <pub-id pub-id-type="pmid">18404389</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
